KR20090101581A - The preparaton of alkenylazetidinone intermediates for carbapenems - Google Patents
The preparaton of alkenylazetidinone intermediates for carbapenemsInfo
- Publication number
- KR20090101581A KR20090101581A KR1020080026799A KR20080026799A KR20090101581A KR 20090101581 A KR20090101581 A KR 20090101581A KR 1020080026799 A KR1020080026799 A KR 1020080026799A KR 20080026799 A KR20080026799 A KR 20080026799A KR 20090101581 A KR20090101581 A KR 20090101581A
- Authority
- KR
- South Korea
- Prior art keywords
- ether
- amino
- azetidinone
- naphthol
- incl
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title description 6
- 229940041011 carbapenems Drugs 0.000 title description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims abstract description 40
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 claims abstract description 25
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims abstract description 24
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 16
- -1 alkenyl azetidinone Chemical compound 0.000 claims abstract description 15
- 239000003446 ligand Substances 0.000 claims abstract description 14
- 235000001258 Cinchona calisaya Nutrition 0.000 claims abstract description 12
- 239000002841 Lewis acid Substances 0.000 claims abstract description 12
- 150000007517 lewis acids Chemical class 0.000 claims abstract description 12
- 229960000948 quinine Drugs 0.000 claims abstract description 12
- 229960001404 quinidine Drugs 0.000 claims abstract description 11
- 229910052723 transition metal Inorganic materials 0.000 claims abstract description 11
- 150000003624 transition metals Chemical class 0.000 claims abstract description 11
- 239000007858 starting material Substances 0.000 claims abstract description 7
- 238000005934 crotylation reaction Methods 0.000 claims abstract description 6
- 229910021607 Silver chloride Inorganic materials 0.000 claims abstract description 5
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052738 indium Inorganic materials 0.000 claims abstract description 5
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims abstract description 5
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 claims abstract description 5
- 101150003085 Pdcl gene Proteins 0.000 claims abstract description 4
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims abstract description 4
- KMPWYEUPVWOPIM-LSOMNZGLSA-N cinchonine Chemical compound C1=CC=C2C([C@@H]([C@H]3N4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-LSOMNZGLSA-N 0.000 claims abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 98
- 229910021617 Indium monochloride Inorganic materials 0.000 claims description 31
- APHGZSBLRQFRCA-UHFFFAOYSA-M indium(1+);chloride Chemical compound [In]Cl APHGZSBLRQFRCA-UHFFFAOYSA-M 0.000 claims description 31
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 claims description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 13
- 229950011260 betanaphthol Drugs 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- LOPKSXMQWBYUOI-UHFFFAOYSA-N 1-amino-2,3-dihydro-1h-inden-2-ol Chemical compound C1=CC=C2C(N)C(O)CC2=C1 LOPKSXMQWBYUOI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims description 3
- LVRCEUVOXCJYSV-UHFFFAOYSA-N CN(C)S(=O)=O Chemical compound CN(C)S(=O)=O LVRCEUVOXCJYSV-UHFFFAOYSA-N 0.000 claims description 3
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- BEYQEHUJCFKFKK-GRHHLOCNSA-N N[C@@H](CO)C1=CC=CC=C1.C1(=CC=CC=C1)[C@@H](N)CO Chemical compound N[C@@H](CO)C1=CC=CC=C1.C1(=CC=CC=C1)[C@@H](N)CO BEYQEHUJCFKFKK-GRHHLOCNSA-N 0.000 claims description 3
- QPEVJIKCOBTDDK-XFNAGHOKSA-N N[C@H](CCC1=CC=CC=C1)O.N[C@H](CCC1=CC=CC=C1)O Chemical compound N[C@H](CCC1=CC=CC=C1)O.N[C@H](CCC1=CC=CC=C1)O QPEVJIKCOBTDDK-XFNAGHOKSA-N 0.000 claims description 3
- 239000003849 aromatic solvent Substances 0.000 claims description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 claims description 3
- 239000007810 chemical reaction solvent Substances 0.000 claims description 3
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims description 3
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 claims description 3
- VVRVZXIIKFLHIH-NRYLJRBGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO.C[C@@H](N)CO VVRVZXIIKFLHIH-NRYLJRBGSA-N 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- JCBPETKZIGVZRE-BYPYZUCNSA-N (2s)-2-aminobutan-1-ol Chemical compound CC[C@H](N)CO JCBPETKZIGVZRE-BYPYZUCNSA-N 0.000 claims 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N 1-butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 1
- 239000011701 zinc Substances 0.000 abstract description 37
- 238000002360 preparation method Methods 0.000 abstract description 9
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 abstract description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 6
- 229910052725 zinc Inorganic materials 0.000 abstract description 6
- PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 abstract 3
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 23
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- YKMONJZIUAOVEM-WDSKDSINSA-N 1beta-methylcarbapenem Chemical compound C[C@H]1C=CN2C(=O)C[C@@H]12 YKMONJZIUAOVEM-WDSKDSINSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- OEYMQQDJCUHKQS-UHFFFAOYSA-N (4-oxoazetidin-2-yl) acetate Chemical compound CC(=O)OC1CC(=O)N1 OEYMQQDJCUHKQS-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- AVMHMVJVHYGDOO-NSCUHMNNSA-N (e)-1-bromobut-2-ene Chemical compound C\C=C\CBr AVMHMVJVHYGDOO-NSCUHMNNSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- UIVUMTFWYSDYQG-RZVRUWJTSA-N N[C@H](CCC)O.N[C@H](CO)CC Chemical compound N[C@H](CCC)O.N[C@H](CO)CC UIVUMTFWYSDYQG-RZVRUWJTSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YNEUKTPESKGPNQ-VIFPVBQESA-N (1s)-1-amino-3-phenylpropan-1-ol Chemical compound N[C@@H](O)CCC1=CC=CC=C1 YNEUKTPESKGPNQ-VIFPVBQESA-N 0.000 description 1
- BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- WKDDRNSBRWANNC-ATRFCDNQSA-N Thienamycin Chemical compound C1C(SCCN)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 WKDDRNSBRWANNC-ATRFCDNQSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
본 발명은 카르바페넴을 위한 알케닐 아제티디논 중간체 제조방법에 관한 것으로, 더욱 상세하게는 하기 화학식 1로 표현되며, 카르바페넴-타입 항생제의 중간체로 사용되는 1β-메틸 카르바페넴을 제조하기 위한 아제티디논 유도체인 4-(알크-2-에닐)-2-아제티디논 의 제조방법에 관한 것이다. The present invention relates to a method for preparing alkenyl azetidinone intermediates for carbapenem, more specifically, represented by the following formula (1), to prepare 1β-methyl carbapenem used as an intermediate of carbapenem-type antibiotics It relates to a method for preparing 4- (alk-2-enyl) -2-azetidinone which is an azetidinone derivative.
단, 상기에서 R1, R2 는 각각 H, Me 이고, R3 는 수소원자 또는 하이드록실-보호 그룹이다.Provided that R 1 and R 2 are each H and Me, and R 3 is a hydrogen atom or a hydroxyl-protecting group.
카르바페넴-타입 항균제는 그램-양성 박테리아로부터 슈도모나스아에루기노사 (Pseudomonas aeruginosa)를 포함하는 그램-음성 박테리아에 이르는 박테리아의 광범위한 스펙트럼에 대해 강한 항균활성을 갖는 탁월한 항균제로, 최근 카르바페넴-타입의 신규한 항균제가 활발하게 개발되고 있다.Carbapenem-type antimicrobials are excellent antimicrobial agents that have strong antimicrobial activity against a broad spectrum of bacteria, from Gram-positive bacteria to Gram-negative bacteria, including Pseudomonas aeruginosa . Types of new antibacterial agents are being actively developed.
카르바페넴 화합물은 통상 하기 화학식 2의 티에나마이신과 같은 카바페넴 골격를 갖는다. Carbapenem compounds usually have a carbapenem skeleton, such as thienamycin of formula (2).
그러나, 1번 위치에 치환체가 없는 카르바페넴 항균제는 화학적으로 불안정하며, 더욱이 생체 내에서는 데하이드로펩티다아제(Dehydropeptidase) 1에 의해 쉽게 대사되는 단점이 있다 (Antimicrob. Agents Chemother. 1982, 22, 62.; J. Antibiotics 1979, 32, 1.).However, carbapenem antimicrobials without substituents at position 1 are chemically unstable and, furthermore, are easily metabolized by Dehydropeptidase 1 in vivo ( Antimicrob. Agents Chemother. 1982, 22, 62. ; J. Antibiotics 1979, 32, 1.).
이를 해결하기 위해, 1번 위치에 베타-배위의 알킬 그룹을 혼입시키면 이러한 카르바페넴 유도체의 안정성이 향상되고 이들 유도체들을 데하이드로펩티다아제 억제제를 가할 필요 없이 단독으로 사용할 수 있다. 그 결과, 입체화학적으로 매우 순수한 카르바페넴으로 전환될 수 있다. To solve this problem, incorporation of beta-coordinated alkyl groups into position 1 improves the stability of these carbapenem derivatives and these derivatives can be used alone without the need to add a dehydropeptidase inhibitor. As a result, it can be converted to stereochemically very pure carbapenems.
종래, 1β-메틸 카르바페넴을 합성하기 위한 출발물질인 4-(알크-2-에닐)-2-아제티디논을 제조하는 방법은 비입체특이적이고 (J. Org. Chem., 50, 3438, 1985), 생성물의 입체 화학은 조절될 수 없어서 공정의 불충분한 실시가능성을 초래하여 목적하는 1β-메틸 카르바페넴의 수득률이 낮다는데 문제가 있다.Conventionally, the method for preparing 4- (alk-2-enyl) -2-azetidinone, which is a starting material for synthesizing 1β-methyl carbapenem, is non-stereospecific ( J. Org. Chem. , 50, 3438 , 1985), the steric chemistry of the product cannot be controlled, resulting in insufficient feasibility of the process, resulting in a low yield of the desired 1β-methyl carbapenem.
다시 말해, 다양한 치환기를 갖는 1β-메틸카르바페넴-타입 유도체의 R- 및 S- 이성질체는 각각 1 : 1의 비율로 수득되어 유용성이 적은 R- 이성질체 또는 적어도 상당량의 R- 이성질체와의 혼합물로 제조되므로 (Chem. Pharm. Bull., 39(3), 663-671, 1991), 이로부터 목적하는 S- 이성질체를 분리하는 것은 어렵고, 비용이 많이 들며 비효율적이었다.In other words, the R- and S-isomers of the 1β-methylcarbapenem-type derivatives having various substituents are obtained in a ratio of 1: 1, respectively, in a mixture with less useful R- isomers or at least a substantial amount of R- isomers. As prepared ( Chem. Pharm. Bull. , 39 (3), 663-671, 1991), it was difficult, costly and inefficient to separate the desired S-isomer from it.
이에 본 발명자들은 원하는 화합물을 더욱 양호한 수율로 수득할 수 있도록 목적 이성질체를 주생성물로 하는 4-(알크-2-에닐)-2-아제티디논, 즉 (4R)-4-[(1S)-1-메틸알릴]-2-아제티디논{(4R)-4-[(1S)-1-Methylallyl]-2-azetidinone} 을 제조하기 위해 예의 노력한 결과, 목적하는 이성질체를 기존 보다 최고 3배 이상 수득할 수 있음을 확인하고 본 발명을 완성하였다.Thus, the present inventors used 4- (alk-2-enyl) -2-azetidinone, i.e., (4R) -4-[(1S)-, with the target isomer as the main product so that the desired compound can be obtained in better yield. As a result of intensive efforts to prepare 1-methylallyl] -2-azetidinone {(4R) -4-[(1S) -1-Methylallyl] -2-azetidinone}, the desired isomer is up to three times higher than before. It was confirmed that it can be obtained and completed the present invention.
결국, 본 발명의 주된 목적은 항균성의 1β-메틸 카르바페넴을 제조하기 위한 주요 중간체인 4-(알크-2-에닐)-2-아제티디논의 목적하는 이성질체를 고수율로 제조하는 입체 특이적 방법을 제공하는데 있다. After all, the main object of the present invention is stereospecific for preparing the desired isomer of 4- (alk-2-enyl) -2-azetidinone, which is the main intermediate for preparing antimicrobial 1β-methyl carbapenem. To provide a method.
상기 목적을 달성하기 위해, 본 발명은 4-아세톡시아제티디논 (4(R)-acetoxyazetidinone, Ⅰ)을 출발물질로 하고, 키랄 리간드(Chiral Ligand), 전이금속, 루이스 산(Lewis acid)의 존재 하에서 크로틸화(crotylation) 시키는 것을 특징으로 하는 베타형(β-form)의 4-(알크-2-에닐)-2-아제티디논(Ⅱ, 화학식 1)의 제조방법을 제공한다.In order to achieve the above object, the present invention uses 4-acetoxyazetidinone (4 (R) -acetoxyazetidinone (I)) as a starting material, chiral ligand (Chiral Ligand), transition metal, Lewis acid (Lewis acid) It provides a method for the preparation of beta (β-form) 4- (alk-2-enyl) -2-azetidinone (II, Formula 1) characterized in that it is crotylation in the presence.
본 발명에 있어서, 상기 키랄 리간드는 신코닌(cinchonine), 신코니딘(cinchonidin), 퀴닌(quinine), 퀴니딘(quinidine), 노르에페드린(norephedrin), 2,2'-비스(디페닐포스피노)-1,1'-비나프틸(BINAP), (S)-(-)-아미노-3-페닐-1-프로판올{(S)-(-)-Amino-3-phenyl-1-propanol}, (R)-(-)-2-페닐글리시놀{(R)-(-)-2-Phenylglycinol}, 아미노-2-인단올(Amino-2-indanol), (S)-(+)-2-아미노-1-부탄올{(S)-(+)-Amino-1-butanol}, O-아세틸신코닌(O-acetylcinchonine), O-아세틸신코니딘(O-acetylcinchonidine), (R)-바이(2-나프톨){(R)-Bi(2-naphthol)}, (S)-바이(2-나프톨){(S)-Bi(2-naphthol)}, S-2-아미노프로판올(S-2-Aminopropanol), R-2-아미노프로판올(R-2-Aminopropanol), O-아세틸퀴닌(O-acetylquinine), O-아세틸퀴니딘(O-acetylquinidine)으로 이루어진 군에서 선택되는 것을 특징으로 하며, 상기 전이금속은 아연(Zn) 또는 인듐(In)인 것을 특징으로 할 수 있다.In the present invention, the chiral ligand is cinchonine, cinchonidin, quinine, quinine, quinidine, norephedrin, 2,2'-bis (diphenylphosphino) ) -1,1'-binafyl (BINAP), (S)-(-)-amino-3-phenyl-1-propanol {(S)-(-)-Amino-3-phenyl-1-propanol} , (R)-(-)-2-phenylglycinol {(R)-(-)-2-Phenylglycinol}, amino-2-indanol, (S)-(+) -2-amino-1-butanol {(S)-(+)-Amino-1-butanol}, O-acetylcinchonine, O-acetylcinchonidine, (R) -Bi (2-naphthol) {(R) -Bi (2-naphthol)}, (S) -bi (2-naphthol) {(S) -Bi (2-naphthol)}, S-2-aminopropanol ( S-2-Aminopropanol), R-2-aminopropanol (R-2-Aminopropanol), O-acetylquinine (O-acetylquinine), O-acetylquinidine (O-acetylquinidine) characterized in that it is selected from the group consisting of In addition, the transition metal may be characterized in that the zinc (Zn) or indium (In).
또한, 본 발명에 있어서, 상기 루이스 산은 AgCl, PdCl, AgOTf, CuCl, CuCN, Cu(OAc)2, InCl3, PbBr2, GaCl3, Ti(OPr)4, CeCl3, Sc(OTf)3, ZnCl2, ZnBr2 로 이루어진 군에서 선택되는 것이 특징이고, 반응용매로는 석유에테르, 이소프로필에테르(IPE), 디에틸에테르, 디부틸에테르, t-부틸메틸에테르, 디옥산 등의 에테르(Ether) 용매; 테트라히드로퓨란(THF), 디알콕시알칸, N,N-디메틸 포름아마이드(N,N-Dimethyl foramide, DMF), 디메틸아세트아마이드, 디메틸술폰아마이드, 디클로로메탄(Dichloromethane, MC), 아세토니트릴(MeCN) 등의 극성용매; 벤젠, 톨루엔 등의 방향족 용매;로 이루어진 군에서 선택되는 1종 이상을 단독 또는 병행하여 사용하는 것을 특징으로 한다.In addition, in the present invention, the Lewis acid is AgCl, PdCl, AgOTf, CuCl, CuCN, Cu (OAc) 2 , InCl 3 , PbBr 2 , GaCl 3 , Ti (OPr) 4, CeCl 3 , Sc (OTf) 3, It is characterized in that it is selected from the group consisting of ZnCl 2 , ZnBr 2 , and the reaction solvent is an ether such as petroleum ether, isopropyl ether (IPE), diethyl ether, dibutyl ether, t-butyl methyl ether, dioxane ) Solvents; Tetrahydrofuran (THF), dialkoxyalkane, N, N-dimethyl foramide (DMF), dimethylacetamide, dimethylsulfonamide, dichloromethane (MC), acetonitrile (MeCN) Polar solvents such as these; It is characterized by using one or more types selected from the group consisting of aromatic solvents such as benzene and toluene alone or in parallel.
본 발명에 따른 제조방법은, 원하는 광학 이성질체를 기존 보다 최고 3배 이상 고수율로 수득하는 것이 가능할 뿐만 아니라, 카르바페넴 항생제의 중간체로 사용되는 1β-메틸 카르바페넴을 제조하기 위한 중요한 중간체인 아제티디논 유도체, 즉 베타형의 4-(알크-2-에닐)-2-아제티디논(화학식 1)을 제공함으로써, 유효한 1β-메틸 카르바페넴 화합물의 합성을 비교적 용이하게 저비용으로 제조하는 것이 가능하여 산업화에 유용하게 이용될 수 있다.The preparation method according to the invention is not only possible to obtain the desired optical isomer in a high yield up to three times higher than conventionally, but also is an important intermediate for preparing 1β-methyl carbapenem used as an intermediate of carbapenem antibiotics. By providing an azetidinone derivative, i.e., the beta form 4- (alk-2-enyl) -2-azetidinone (Formula 1), the synthesis of an effective 1β-methyl carbapenem compound is relatively easy and at low cost. It is possible to be usefully used for industrialization.
이하, 본 발명을 상세하게 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.
본 발명은 4-아세톡시아제티디논(4(R)-acetoxyazetidinone, Ⅰ)을 출발물질로 하고, 키랄 리간드(Chiral Ligand), 전이금속, 루이스 산(Lewis acid)의 존재 하에서 크로틸화(crotylation) 시켜 상기 화학식 1로 표현되는 4-(알크-2-에닐)-2-아제티디논(Ⅱ)을 제조하는 방법을 제공한다.The present invention uses 4-acetoxyazetidinone (4 (R) -acetoxyazetidinone (I) as a starting material, and crotylation in the presence of chiral ligands, transition metals and Lewis acids. To provide 4- (alk-2-enyl) -2-azetidinone (II) represented by Chemical Formula 1 above.
본 발명의 바람직한 실시양태는 하기와 같이 나타낼 수 있다.Preferred embodiments of the present invention can be represented as follows.
단, 상기에서 R 은 수소원자 또는 하이드록실-보호 그룹으로, 특히 TBDMS(t-부틸디메틸실릴기)인 것이 바람직하다. However, in the above, R is a hydrogen atom or a hydroxyl-protecting group, particularly preferably TBDMS (t-butyldimethylsilyl group).
본 발명에 있어서, 상기 키랄리간드는 신코닌(cinchonine), 신코니딘(cinchonidin), 퀴닌(quinine), 퀴니딘(quinidine), 노르에페드린(norephedrin), 2,2'-비스(디페닐포스피노)-1,1'-비나프틸(BINAP), (S)-(-)-아미노-3-페닐-1-프로판올{(S)-(-)-Amino-3-phenyl-1-propanol}, (R)-(-)-2-페닐글리시놀{(R)-(-)-2-Phenylglycinol}, 아미노-2-인단올(Amino-2-indanol), (S)-(+)-2-아미노-1-부탄올{(S)-(+)-Amino-1-butanol}, O-아세틸신코닌(O-acetylcinchonine), O-아세틸신코니딘(O-acetylcinchonidine), (R)-바이(2-나프톨){(R)-Bi(2-naphthol)}, (S)-바이(2-나프톨){(S)-Bi(2-naphthol)}, S-2-아미노프로판올(S-2-Aminopropanol), R-2-아미노프로판올(R-2-Aminopropanol), O-아세틸퀴닌(O-acetylquinine), O-아세틸퀴니딘(O-acetylquinidine)으로 이루어진 군에서 선택되는 것이 바람직하며, 상기 전이금속은 아연(Zn) 또는 인듐(In)인 것이 바람직하다.In the present invention, the chiral ligand is cinchonine (cinchonine), cinchonidin (cinchonidin), quinine (quinine), quinidine (quinidine), norephedrin (norephedrin), 2,2'-bis (diphenylphosphino ) -1,1'-binafyl (BINAP), (S)-(-)-amino-3-phenyl-1-propanol {(S)-(-)-Amino-3-phenyl-1-propanol} , (R)-(-)-2-phenylglycinol {(R)-(-)-2-Phenylglycinol}, amino-2-indanol, (S)-(+) -2-amino-1-butanol {(S)-(+)-Amino-1-butanol}, O-acetylcinchonine, O-acetylcinchonidine, (R) -Bi (2-naphthol) {(R) -Bi (2-naphthol)}, (S) -bi (2-naphthol) {(S) -Bi (2-naphthol)}, S-2-aminopropanol ( S-2-Aminopropanol), R-2-Aminopropanol, O-acetylquinine (O-acetylquinine), O-acetylquinidine (O-acetylquinidine) is preferably selected from the group consisting of , The transition metal is preferably zinc (Zn) or indium (In).
또한, 본 발명에 있어서, 상기 루이스산은 AgCl, PdCl, AgOTf, CuCl, CuCN, Cu(OAc)2, InCl3, PbBr2, GaCl3, Ti(OPr)4, ZnCl2, ZnBr2,CeCl3, Sc(OTf)3 로 이루어진 군에서 선택되는 것이 바람직하다.In addition, in the present invention, the Lewis acid is AgCl, PdCl, AgOTf, CuCl, CuCN, Cu (OAc) 2 , InCl 3 , PbBr 2 , GaCl 3 , Ti (OPr) 4, ZnCl 2 , ZnBr 2 , CeCl 3 , It is preferably selected from the group consisting of Sc (OTf) 3 .
또한, 본 발명에 있어서, 반응용매로는 석유에테르, 이소프로필에테르(IPE), 디에틸에테르, 디부틸에테르, t-부틸메틸에테르, 디옥산 등의 에테르(Ether) 용매; 테트라히드로퓨란(THF), 디알콕시알칸, N,N-디메틸 포름아마이드(N,N-Dimethyl foramide, DMF), 디메틸아세트아마이드, 디메틸술폰아마이드, 디클로로메탄(Dichloromethane, MC), 아세토니트릴(MeCN) 등의 극성용매; 벤젠, 톨루엔 등의 방향족 용매;로 이루어진 군에서 선택되는 1종 이상을 단독 또는 병행하여 사용할 수 있는데, 특히 디에틸에테르, THF, DMF, MC, MeCN로 이루어진 군에서 선택되는 1종 이상인 것이 바람직하다.In the present invention, the reaction solvent may be an ether solvent such as petroleum ether, isopropyl ether (IPE), diethyl ether, dibutyl ether, t-butyl methyl ether, dioxane; Tetrahydrofuran (THF), dialkoxyalkanes, N, N-dimethyl foramide (DMF), dimethylacetamide, dimethylsulfonamide, dichloromethane (MC), acetonitrile (MeCN) Polar solvents such as these; At least one selected from the group consisting of aromatic solvents such as benzene and toluene; may be used alone or in combination. Particularly, at least one selected from the group consisting of diethyl ether, THF, DMF, MC, and MeCN is preferable. .
또한, 본 발명에 있어서, 상기에서 키랄 리간드는 0.005 ~ 3 당량, 바람직하게는 0.025 ~ 1 당량 첨가되는 것이 좋고, 상기 루이스 산은 0.005 ~ 3 당량, 바람직하게는 0.025 ~ 1 당량 첨가되는 것이 좋으며, 반응 온도범위는 0 ~ 50℃, 바람직하게는 0 ~ 35℃인 것이 좋다. In the present invention, the chiral ligand is preferably added in an amount of 0.005 to 3 equivalents, preferably 0.025 to 1 equivalent, and the Lewis acid is preferably added in an amount of 0.005 to 3 equivalents, preferably 0.025 to 1 equivalent, The temperature range is 0 to 50 ° C, preferably 0 to 35 ° C.
이하, 실시 예에 의하여 본 발명을 더욱 상세히 설명하고자 한다.Hereinafter, the present invention will be described in more detail with reference to Examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시 예에 한정되는 것은 아니다. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.
실시예Example 1. 4-(R)-[1- 4- (R)-[1- methylmethyl (( allylallyl )-)- azetidinoneazetidinone ]의 제조 Ⅰ Manufacture of I
글로브 박스에서 둥근 바닥 플라스크에 4-아세톡시아제티디논(4(R)-acetoxyasetidinone, AOSA) 0.1 g(0.34 mmol), 신코닌 0.044 g(0.5 당량), 염화인듐 0.033 g(0.5 당량)를 넣고 아르곤 기체를 채워 밀봉하였다. 여기에 에테르 5 ㎖를 투입하여 반응온도를 25 ~ 35℃으로 유지하면서 크로틸 브롬 0.081 g(2.0 당량)를 천천히 가하고, 30분 후에 아연 0.04 g(2.0 당량)를 첨가한 후 29℃에서 총 4시간에 걸쳐 교반하되, 반응의 진행여부는 TLC(ether : n-hexane = 2 : 1)로 확인하였다. 상기 반응물에 다시 포화 염화암모늄 용액 10 ㎖ 및 에테르 20 ㎖를 가하고 2 ~ 3분 동안 교반한 다음, 분별 깔때기를 사용하여 물층을 제거하였다. 물층을 제거한 유기층에 무수 소듐 셀페이트를 2 ~ 3 g 투입하고 15분간 교반하여 유기층 속에 남아있는 물층을 완전하게 제거한 후 글래스 필터로 여과하고 유기용매(에테르)로 세척하여 유기층을 감압 농축하였다. In a glove box, add 0.1 g (0.34 mmol) of 4-acetoxyasetidinone (4 (R) -acetoxyasetidinone (AOSA)), 0.044 g (0.5 equiv) of cinconine, and 0.033 g (0.5 equiv) of indium chloride in a round bottom flask. Sealed with argon gas. 5 ml of ether was added thereto, and 0.081 g (2.0 equivalents) of crotyl bromide was slowly added while maintaining the reaction temperature at 25 to 35 ° C. After 30 minutes, 0.04 g (2.0 equivalents) of zinc was added, followed by a total of 4 at 29 ° C. Stirring over time, the progress of the reaction was confirmed by TLC (ether: n-hexane = 2: 1). 10 ml of saturated ammonium chloride solution and 20 ml of ether were added to the reaction mixture, stirred for 2-3 minutes, and then the water layer was removed using a separatory funnel. 2-3 g of anhydrous sodium sulfate was added to the organic layer from which the water layer was removed, followed by stirring for 15 minutes to completely remove the remaining water layer in the organic layer, followed by filtration with a glass filter, washing with an organic solvent (ether), and concentrating the organic layer under reduced pressure.
상기와 같은 과정으로 베타형 : 알파형의 비율이 2.5 : 1인 흰색의 4(R)-[1-methyl(allyl)-azetidinone]을 결정 형태로 93 ㎎(수득율 95%)을 수득하였다. As described above, 93 mg (yield 95%) of white 4 (R)-[1-methyl (allyl) -azetidinone] having a beta-type alpha ratio of 2.5: 1 was obtained in crystalline form.
(1) 베타형(β-form)(1) beta form (β-form)
1H-NMR (400MHz, CDCl3): 0.02~0.09(6H), 0.83~0.94(9H), 1.03~1.07(3H), 1.12~1.18(3H), 1.22~1.34(3H), 2.25~2.34(1H), 2.79~2.80(1H), 3.46~3.48(1H), 4.13~4.23(1H), 5.02~5.13(2H), 5.68~5.81(1H), 6.51(1H) 1 H-NMR (400 MHz, CDCl 3 ): 0.02 to 0.09 (6H), 0.83 to 0.94 (9H), 1.03 to 1.07 (3H), 1.12 to 1.18 (3H), 1.22 to 1.34 (3H), 2.25 to 2.24 ( 1H), 2.79-2.80 (1H), 3.46-3.48 (1H), 4.13-4.23 (1H), 5.02-5.13 (2H), 5.68-5.81 (1H), 6.51 (1H)
(2) 알파형(α-form)(2) alpha-form
1H-NMR (400MHz, CDCl3): 0.02~0.09(6H), 0.83~0.94(9H), 1.03~1.07(3H), 1.12~1.18(3H), 1.22~1.34(3H), 2.19~2.24(1H), 2.75~2.77(1H), 3.38~3.40(1H), 4.13~4.23(1H), 5.02~5.13(2H), 5.61~5.70(1H), 6.29(1H) 1 H-NMR (400 MHz, CDCl 3 ): 0.02 to 0.09 (6H), 0.83 to 0.94 (9H), 1.03 to 1.07 (3H), 1.12 to 1.18 (3H), 1.22 to 1.34 (3H), 2.19 to 2.24 ( 1H), 2.75-2.77 (1H), 3.38-3.40 (1H), 4.13-4.23 (1H), 5.02-5.13 (2H), 5.61-5.70 (1H), 6.29 (1H)
실시예 2. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅱ Example 2. Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] II
상기 실시예 1과 동일한 방법으로 제조하되, 에테르 2.5 ㎖와 아연을 동시에 첨가하여 제조하고, 베타형 : 알파형의 비율이 2.0 : 1인 흰색의 4(R)-[1-methyl(allyl)-azetidinone]을 결정 형태로 수득하였다(수득율 95%). Prepared in the same manner as in Example 1, but was prepared by adding 2.5 ml of ether and zinc at the same time, the beta form of the alpha form ratio of 2.0: 1 4 (R)-[1-methyl (allyl)- azetidinone] was obtained in crystalline form (yield 95%).
실시예 3 ~ 26. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅲ Examples 3 to 26. Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] III.
출발물질로서 0.3 mmol의 ASOA를 사용하여 상기 실시예 2와 동일한 방법으로 제조하고, 이때 사용한 키랄 리간드, 루이스산, 전이금속 및 용매는 하기의 표 1에 수득 비율과 함께 나타내었다. Using 0.3 mmol of ASOA as a starting material, the preparation was carried out in the same manner as in Example 2, and the chiral ligand, Lewis acid, transition metal, and solvent used were shown in Table 1 below with the obtained ratios.
실시예 27. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅳ Example 27 Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] IV
글로브 박스에서 둥근 바닥 플라스크에 4-아세톡시아제티디논(4-(R)-acetoxyasetidinone, AOSA) 200 ㎎(0.69 mmol), 퀴닌(quinine) 5.6 ㎎(2.5 mol%), 염화인듐 3.8 ㎎(2.5 mol%)을 넣고 아르곤 기체를 채워 밀봉하였다. 여기에 에테르 5㎖를 투입하여 반응온도를 25 ~ 35℃으로 유지하면서 크로틸 브롬 0.143 ㎖를 천천히 가하고, 30분 후에 아연 90.8 ㎎를 첨가하여 29℃에서 총 6시간 에 걸쳐 교반하되, 반응물은 TLC(ether : n-hexane = 2 : 1)로 확인하였다. In a round bottom flask, 4-acetoxyazetidinone (4- (R) -acetoxyasetidinone (AOSA) 200 mg (0.69 mmol), quinine 5.6 mg (2.5 mol%), indium chloride 3.8 mg (2.5) mol%) was added and sealed with argon gas. To this was added 5 ml of ether, slowly adding 0.143 ml of crotyl bromine while maintaining the reaction temperature at 25 to 35 ° C., and after 30 minutes, 90.8 mg of zinc was added and stirred at 29 ° C. for a total of 6 hours. It was confirmed that (ether: n-hexane = 2: 1).
상기 반응물에 다시 포화 염화암모늄 용액 20 ㎖ 및 에테르 20 ㎖를 가하고 2 ~ 3분 동안 교반한 다음, 분별 깔때기를 사용하여 물층을 제거하였다. 물층을 제거한 유기층에는 무수 소듐 셀페이트를 2 ~ 3 g 투입하고 15분간 교반하여 유기층 속에 남아있는 물층을 완전하게 제거한 후 글래스 필터로 여과시키고 유기용매 에테르로 세척하여 유기층을 감압 농축하였다. To the reaction was added 20 ml of saturated ammonium chloride solution and 20 ml of ether and stirred for 2 to 3 minutes, and then the water layer was removed using a separatory funnel. Anhydrous sodium sulphate was added to the organic layer from which the water layer was removed and stirred for 15 minutes to completely remove the water layer remaining in the organic layer, filtered through a glass filter, washed with an organic solvent ether, and concentrated under reduced pressure.
상기와 같은 과정으로 베타형 : 알파형의 비율이 3 : 1인 흰색의 4(R)-[1-methyl(allyl)-azetidinone]을 결정 형태로 수득하였다(수득율 95%). In the same manner as above, white 4 (R)-[1-methyl (allyl) -azetidinone] having a beta-alpha ratio of 3: 1 was obtained in crystalline form (yield 95%).
실시예 28. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅴ Example 28 Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] V
상기 실시예 27와 동일한 방법으로 제조하되, 에테르 10 ㎖와 아연을 동시에 첨가하여 제조하고, 베타형 : 알파형의 비율이 3 : 1인 흰색의 4(R)-[1-methyl(allyl)-azetidinone]을 결정 형태로 수득하였다(수득율 95%). Prepared in the same manner as in Example 27, except that 10 ml of ether and zinc were added at the same time, and the beta-alpha-form ratio was 3: 1 in white 4 (R)-[1-methyl (allyl)-. azetidinone] was obtained in crystalline form (yield 95%).
실시예 29 ~ 36. 4-(R)-[1-methyl(allyl)-azetidinone]의 제조 Ⅵ Examples 29-36 Preparation of 4- (R)-[1-methyl (allyl) -azetidinone] VI
출발물질로서 0.69 mmol의 ASOA를 사용하여, 상기 실시예 27과 동일하게 반응을 진행시킨 결과, 표제 화합물이 하기 표 2와 같이 제조되었다.Using 0.69 mmol of ASOA as a starting material, the reaction was carried out in the same manner as in Example 27, whereby the title compound was prepared as shown in Table 2 below.
실시예Example 37. 4-(R)-[1- 37. 4- (R)-[1- methylmethyl (( allylallyl )-)- azetidinoneazetidinone ]의 제조 Ⅶ Manufacturing of Ⅶ
글로브 박스에서 둥근 바닥 플라스크에 (3R,4R)-4-acetoxy-3-{(R)-l'[(t-butyldimethylsilyl)oxy]ethyl}-2-azetidinone 1.44 g(5.0 mmol), 신코니딘 (cinchonidine) 0.029 g(2.0 mol%), 염화 인듐 0.022 g(2.0 mol%)를 넣고 아르곤 기체를 채워 밀봉하였다. 여기에 에테르 42 ㎖를 투입하여 반응온도를 25 ~ 30℃ 으로 유지하면서 크로틸 브롬 1.0 ㎖(2.0 당량)를 천천히 가하고, 30분 후에 아연 0.65 g(2.0 당량)를 첨가하여 29℃에서 총 4시간 에 걸쳐 교반 하되, 반응의 진행여부는 TLC(ether : n-hexane = 2 : 1)로 확인하였다. 상기 반응물에 다시 포화 염화암모늄 용액 10 ㎖ 및 에테르 20 ㎖를 가지고 2번 세척하고 세척 후 Na2SO4 로 수분을 제거하여 유기층을 감압 농축하였다. 상기와 같은 과정으로 베타형 : 알파형의 비율이 3.2 : 1인 흰색의 생성물을 동일한 수율로 얻었다(수득율 95%).In a round bottom flask in a glove box, 1.44 g (5.0 mmol) of (3R, 4R) -4-acetoxy-3-{(R) -l '[(t-butyldimethylsilyl) oxy] ethyl} -2-azetidinone, cinconidine (cinchonidine) 0.029 g (2.0 mol%) and indium chloride 0.022 g (2.0 mol%) were added and sealed with argon gas. 42 ml of ether was added thereto, and 1.0 ml (2.0 equivalents) of crotyl bromide was slowly added while maintaining the reaction temperature at 25 to 30 ° C. After 30 minutes, 0.65 g (2.0 equivalents) of zinc was added thereto for a total of 4 hours at 29 ° C. Stirring over, the progress of the reaction was confirmed by TLC (ether: n-hexane = 2: 1). The reaction was washed twice with 10 ml of saturated ammonium chloride solution and 20 ml of ether. After washing, the organic layer was concentrated under reduced pressure by removing water with Na 2 SO 4 . In the same manner as above, a white product having a ratio of beta form to alpha form of 3.2: 1 was obtained in the same yield (yield 95%).
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080026799A KR100969217B1 (en) | 2008-03-24 | 2008-03-24 | Process for preparing alkenyl azetidinone intermediates for carbapenem |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080026799A KR100969217B1 (en) | 2008-03-24 | 2008-03-24 | Process for preparing alkenyl azetidinone intermediates for carbapenem |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090101581A true KR20090101581A (en) | 2009-09-29 |
KR100969217B1 KR100969217B1 (en) | 2010-07-09 |
Family
ID=41359311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080026799A KR100969217B1 (en) | 2008-03-24 | 2008-03-24 | Process for preparing alkenyl azetidinone intermediates for carbapenem |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100969217B1 (en) |
-
2008
- 2008-03-24 KR KR1020080026799A patent/KR100969217B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR100969217B1 (en) | 2010-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4778883A (en) | 3-(CHFCH3)-azetidinone intermediates | |
DE69526443T2 (en) | 2-SILYLOXY-TETRAHYDROTHIENOPYRIDINE, ITS SALT AND METHOD FOR THE PRODUCTION THEREOF | |
EP0331524B1 (en) | Synthesis of trichostatins | |
JPH0557980B2 (en) | ||
EP0167155B1 (en) | Beta-lactam compound and preparing thereof | |
JPH032157B2 (en) | ||
US20090023915A1 (en) | Process for the Preparation of Faropenem | |
KR100969217B1 (en) | Process for preparing alkenyl azetidinone intermediates for carbapenem | |
US5071966A (en) | Process for preparing an enol silyl ether compound | |
DE68921306T2 (en) | Process for the preparation of 4-acyloxy-2-azetidinone derivatives. | |
US4767853A (en) | Synthesis of 1-(allyloxycarbonyl)-methyl-3-(hydroxyethyl)-4-beta-naphthoxythiocarbonylthio-2-azetidinones and hydroxy protected analogs thereof | |
US4511509A (en) | 3-Alkylidine azetidine compound and their production | |
JP3954670B2 (en) | Preparation of carbapenem antibiotic intermediates | |
JPH04368365A (en) | Production of azetidinone derivative | |
US4709064A (en) | β-N-substituted aminothiol ester and process for preparing the same | |
DE3408196C2 (en) | ||
US4948885A (en) | Synthesis of azetidinones | |
KR100959027B1 (en) | Method for preparing penem intermediate using zinc compound as cocatalyst | |
US5053502A (en) | Anhydro penicillin derivatives | |
AT393839B (en) | Stereocontrolled process for the preparation of novel penem compounds | |
DE69618570T2 (en) | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE TRANS-VINYL SULFIDAL ALCOHOLS | |
US5075438A (en) | Synthesis of azetidinones | |
KR20040099963A (en) | Chiral 2-azetidinone compounds, process and use thereof | |
JP2012506843A (en) | 1,3 imidazolidine derivatives and their use in the production of carbapenem | |
US4876338A (en) | Synthesis of azetidinones using CuCl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20080324 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20100216 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20100701 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20100702 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20100705 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20130906 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20130906 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140414 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20140414 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150428 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20150428 Start annual number: 6 End annual number: 6 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20170609 |